CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
| Autor: | Eloisa Jantus-Lewintre, Fernando Aranda, Inês Simões, Carlos Camps, Yvonne M. Saenger, Silvia Calabuig-Fariñas, Rafael Rosell, Esther Carreras, Rafael Sirera, Sheila Zúñiga, Andrea Moreno-Manuel, Francisco Lozano |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Lymphocyte non-small cell lung cancer (NSCLC) 03 medical and health sciences 0302 clinical medicine Internal medicine medicine melanoma Lung cancer immune checkpoint Survival analysis business.industry Melanoma Marcadors tumorals Biochemical markers CD6 medicine.disease Immune checkpoint CD5 030104 developmental biology medicine.anatomical_structure Real-time polymerase chain reaction 030220 oncology & carcinogenesis Tumor markers Marcadors bioquímics Càncer de pulmó Original Article business |
| Zdroj: | Translational Lung Cancer Research r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname Dipòsit Digital de la UB Universidad de Barcelona Transl Lung Cancer Res r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF) r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA r-CIPF: Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF) Centro de Investigación Principe Felipe (CIPF) |
| ISSN: | 2226-4477 2218-6751 |
| Popis: | Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6-two lymphocyte surface markers involved in the fine tuning of TCR signaling-as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC).; Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC.; Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, P=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher CD5/CD4 + ratio had significantly improved prognosis. Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early stages of NSCLC (HR=0.554; 95% CI, 0.360-0.853; P=0.007). Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and CD6 expression although CD6 expression alone did not reach significant prognostic value in our NSCLC training cohort.; Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance. 2020 Translational Lung Cancer Research. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|